Icotrokinra Holds Up at Two Years in Plaque Psoriasis
Johnson & Johnson reports robust two-year data for ICOTYDE (icotrokinra) in plaque psoriasis across adults and adolescents, positioning the oral IL-23-targeting candidate as a durability story.
Topic
Long Term Efficacy
Topic
Long Term Efficacy
Nemolizumab holds three-year atopic dermatitis response curve
NEMLUVIO (nemolizumab) sustained atopic dermatitis responses across three years in a long-term extension cohort, per PharmaTimes.…
Alumis reports 48-week psoriasis symptom data
Alumis has reported 48-week psoriasis symptom data from its TYK2 inhibitor program, extending durability evidence well past the s…
Lebrikizumab for Atopic Dermatitis: 4-Year Clearance, Itch Relief
Lebrikizumab sustained skin clearance and itch reduction in atopic dermatitis across four years of follow-up, per HCPLive's long-…
Nemolizumab Sustains Atopic Dermatitis Control Through 3 Years
Long-term data show nemolizumab maintained skin clearance and itch control in atopic dermatitis patients through 3 years of conti…
Icotrokinra Holds Skin Clearance at High-Impact Psoriasis Sites at 2 Years
Icotrokinra sustained skin clearance at high-impact psoriasis sites through 2 years, per Dermatology Times. The milestone extends…
Tildrakizumab Delivers Long-Term Control in Hard-to-Treat Psoriasis Areas
AJMC reports tildrakizumab sustained long-term psoriasis control in hard-to-treat areas such as scalp, palms and soles, strengthe…